MJ Biz reports Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex. The Ireland-based company, according to Green Market Report, filed its 2023 patent-enforcement lawsuit against a dozen alleged infringers, including: Alkem Laboratories API Pharma Tech Apotex Ascent Pharmaceuticals Biophore Pharma InvaGen Pharmaceuticals and its parent, Cipla USA Lupin MSN Pharmaceuticals Padagis […]
Time Out: Jazz dismisses final patent claim involving cannabinoid epilepsy drug
